Dr. Lal PathLabs Q3 PAT seen up 27.4% YoY to Rs. 54.1 cr: Prabhudas Lilladher

Gennex Laboratories | Premier Capital & Securities acquired 10 lakh shares in company at Rs 4.65 per share on the BSE. (Image: gennexlab.com)

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

live

• bselive
• nselive

Volume

Todays L/H

More

×

Prabhudas Lilladher has come out with its third quarter (October-December’ 20) earnings estimates for the Pharma sector. The brokerage house expects Dr. Lal PathLabs to report net profit at Rs. 54.1 crore up 27.4% year-on-year (down 20.9% quarter-on-quarter).

Net Sales are expected to increase by 15.3 percent Y-o-Y (down 1.8 percent Q-o-Q) to Rs. 4,234.6 crore, according to Prabhudas Lilladher.

Earnings before interest, tax, depreciation and amortisation (EBITDA) are likely to rise by 24.9 percent Y-o-Y (down 19.2 percent Q-o-Q) to Rs. 82.3 crore.

Disclaimer: The views and investment tips expressed by investment experts on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

Read More